Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

2.

Vascular protective effects of angiotensin converting enzyme inhibitors and their relation to clinical events.

Enseleit F, Hürlimann D, Lüscher TF.

J Cardiovasc Pharmacol. 2001 Apr;37 Suppl 1:S21-30. Review.

PMID:
11392475
3.
4.

Angiotensin converting enzyme inhibitors and vascular protection in hypertension.

Ruschitzka F, Noll G, Lüscher TF.

J Cardiovasc Pharmacol. 1999 Aug;34 Suppl 1:S3-12. Review.

PMID:
10499558
5.

Angiotensin, ACE-inhibitors and endothelial control of vasomotor tone.

Lüscher TF.

Basic Res Cardiol. 1993;88 Suppl 1:15-24. Review.

PMID:
8357330
6.

Nitric oxide, angiotensin II, and hypertension.

Zhou MS, Schulman IH, Raij L.

Semin Nephrol. 2004 Jul;24(4):366-78. Review.

PMID:
15252776
7.

Combination of ACE inhibitors and calcium antagonists: a logical approach.

Ruschitzka FT, Noll G, Lüscher TF.

J Cardiovasc Pharmacol. 1998;31 Suppl 2:S5-16. Review.

PMID:
9605596
8.

Interaction between nitric oxide and angiotensin II in the endothelium: role in atherosclerosis and hypertension.

Schulman IH, Zhou MS, Raij L.

J Hypertens Suppl. 2006 Mar;24(1):S45-50. Review.

PMID:
16601573
9.

Endothelium-dependent effects of converting-enzyme inhibitors.

Vanhoutte PM, Boulanger CM, Illiano SC, Nagao T, Vidal M, Mombouli JV.

J Cardiovasc Pharmacol. 1993;22 Suppl 5:S10-6. Review.

PMID:
7508046
10.

Modulating atherosclerosis through inhibition or blockade of angiotensin.

Rosenson RS.

Clin Cardiol. 2003 Jul;26(7):305-11. Review.

11.

Angiotensin II, nitric oxide, and end-organ damage in hypertension.

Bataineh A, Raij L.

Kidney Int Suppl. 1998 Dec;68:S14-9. Review.

PMID:
9839277
12.

Angiotensin-converting enzyme and vascular remodeling.

Heeneman S, Sluimer JC, Daemen MJ.

Circ Res. 2007 Aug 31;101(5):441-54. Review.

13.
14.

Vascular protection: current possibilities and future perspectives.

Lüscher TF.

Int J Clin Pract Suppl. 2001 Jan;(117):3-6. Review.

PMID:
11715356
15.

Risk factor-induced cardiovascular remodeling and the effects of angiotensin-converting enzyme inhibitors.

Galderisi M, de Divitiis O.

J Cardiovasc Pharmacol. 2008 Jun;51(6):523-31. doi: 10.1097/FJC.0b013e31817751a7. Review.

PMID:
18520954
16.

Cell biology and genetics of angiotensin in cardiovascular disease.

Dzau VJ.

J Hypertens Suppl. 1994 Jul;12(4):S3-10. Review.

PMID:
7965271
17.

Cardiovascular hypertrophy: role of angiotensin II and bradykinin.

Waeber B, Brunner HR.

J Cardiovasc Pharmacol. 1996;27 Suppl 2:S36-40. Review.

PMID:
8723398
18.

The endothelium in acute coronary syndromes.

Noll G, Lüscher TF.

Eur Heart J. 1998 Apr;19 Suppl C:C30-8. Review.

PMID:
9597423
19.

The renin-angiotensin-aldosterone system: a specific target for hypertension management.

Weir MR, Dzau VJ.

Am J Hypertens. 1999 Dec;12(12 Pt 3):205S-213S. Review.

PMID:
10619573
20.

Supplemental Content

Support Center